Global demand outlook improves for Nuwiq hemophilia treatment market

The Nuwiq (Vihuma) market is expected to accelerate through 2035 as hemophilia A diagnoses rise, healthcare spending grows and demand increases for personalized prophylaxis and home infusion. North America led the market in 2025, while Asia-Pacific is projected to be the fastest-growing region.

Why it matters: - Nuwiq (Vihuma) is a recombinant factor VIII therapy used to treat and prevent bleeding in people with hemophilia A. - Demand for the therapy is tied to rising diagnosis rates, broader access to specialty care and a shift toward individualized treatment plans. - The market outlook matters because hemophilia A is a lifelong bleeding disorder that requires ongoing management.

What happened: - The Business Research Company published its Nuwiq (Vihuma) Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 9, 2026. - The report says the Nuwiq (Vihuma) market is expanding steadily as global demand increases. - The report includes forecasts, regional analysis and new 2026 report features such as market attractiveness scoring, TAM analysis, company scoring matrices, forecasting dashboards and updated graphics. - The report offers a free sample and the full report.

The details: - Nuwiq (Vihuma) is designed to replace missing or deficient factor VIII, which is essential for normal blood clotting. - Historical market growth has been supported by increased hemophilia A diagnoses, limits of plasma-derived therapies, recombinant protein technologies, better patient survival and more specialized hemophilia treatment centers. - The report expects future growth from demand for personalized dosing regimens, wider use of long-term prophylaxis, ongoing recombinant therapy pipelines, more rare blood disorder research funding and more home infusion treatment. - Forecast-period trends include broader use of recombinant coagulation therapies, preference for factor VIII derived from human cell lines, a stronger focus on prophylactic management, expansion of home-based treatment and greater attention to safety and purity. - The report says North America held the largest regional share in 2025. - The report says Asia-Pacific is expected to grow the fastest over the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - NIH data cited in the report said 6,662 males were diagnosed with hemophilia A in the UK between April 2022 and March 2023. - The UK Office for National Statistics reported a 5.6% nominal increase in total healthcare expenditure from 2022 to 2023, after 0.9% growth the year before. - The Personalized Medicine Coalition reported that the US FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022.

Between the lines: - The market story is less about a single drug and more about a broader shift in hemophilia care toward recombinant products, prevention-first treatment and home-based administration. - Rising healthcare spending and stronger personalized medicine adoption are supporting access to advanced therapies, which can widen the addressable patient base. - North America’s current lead suggests mature diagnosis and treatment infrastructure, while Asia-Pacific’s growth outlook points to room for expansion as access improves.

What's next: - The report expects the market to keep benefiting from recombinant therapy development and more use of prophylactic, individualized care. - Home infusion and other home-based treatment models are likely to become more important as patients and providers seek convenience and long-term management. - Regional competition is likely to intensify as Asia-Pacific demand accelerates and more hemophilia care capacity develops.

The bottom line: - The Nuwiq (Vihuma) market is gaining momentum because hemophilia A treatment is moving toward personalized, preventive and home-based care, with global demand still rising.